Figure 3.

(A and B) ELISA analysis showed a significant reduction in oxLDL-induced IL-1β release from HCAECs following inhibition of both caspase-1 (YVAD) (A) and the NLRP3 inflammasome (MCC950) (B). (C and D) The release of IL-1β from oxLDL-treated HCASMCs was only significantly reduced upon inhibition of caspase-1 (C) and not the NLRP3 inflammasome (D). Data are expressed as mean ± s.e.m. and analysed using a one-way ANOVA and a Bonferroni post-hoc test, ****P < 0.0001, n = 3 independent donors.